Skip to main content

Table 2 Tuberculosis screening tests, treatment, and risk factors for tuberculosis in Portuguese and Brazilian juvenile idiopathic arthritis populations

From: Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients

 

Portuguese

Brazilian

p value

Total

Number of patients (%)

188 (64.4)

104 (35.6)

292 (100)

Reason for screening (%)

  

< 0.001

 

 At disease onset

55 (29.3)

63 (60.6)

118 (0.4)

 Before treatment

127 (67.7)

36 (34.6)

163 (5.8)

 Other*1

6 (3.2)

5 (4.8)

11 (3.8)

Age at screening

    

 At JIA onset

8.9 ± 5.4

7.2 ± 4.2

0.064

 ± 4.9

 At treatment start

    

 Before bDMARDs (years of age)

11.9 ± 5.8

9.5 ± 2.8

0.162

11.5 ± 5.6

 Number (%)

72 (38.3)

15 (14.4)

< 0.001

87 (29.8)

 Before cDMARDs (years of age)

9.6 ± 5.1

9.2 ± 3.7

0.692

9.5 ± 4.7

 Number (%)

55 (29.3)

21 (20.2)

0.091

76 (26)

 Other*1

18.5 ± 2.1

5.4 ± 3.5

< 0.001

11.2 ± 7.4

TST performed as single test (%)

92 (48.9)

102 (98.1)

< 0.001

194 (66.4)

 TST ≥ 5 mm (%)

8 (8.7)

11 (10.8)

0.625

19 (9.8)

IGRA performed as single test (%)

13 (6.9)

1 (1)

0.023

14 (4.8)

 IGRA positive (%)

0 (0)

1 (100)

0.071

1 (7.1)

TST and IGRA performed (%)

83 (44.1)

1 (1)

< 0.001

84 (28.8)

 TST ≥ 5 mm (%)

10 (12)

0

0.999

10 (11.9)

 IGRA positive (%)

3 (3.6)

0

0.999

3 (3.6)

 TST and IGRA positive (%)

0

0

0

LTBI therapy (Isoniazid) (%)

20 (10.6)

11 (10.6)

0.999

31 (10.6)

Chest X-ray performed (%)

145 (77.1)

58 (55.8)

< 0.001

203 (69.5)

Abnormal chest X-ray (%)*2

4 (2.8)

4 (6.9)

0.171

8 (3.9)

Immigrant from highrisk countries (%)

3 (1.6)

1 (1)

0.547

4 (1.4)

Exposure by contact TB cases (%)

3 (1.6)

3 (2.9)

0.592

6 (2.1)

Tuberculosis treatment (%)

1 (0.5)

2 (1.9)

0.290

3 (1)

Background of low socio-educational level

37 (19.7)

21 (20.2)

0.916

58 (19.9)

  1. p-value < 0.05 are shown in bold
  2. JIA, Juvenile Idiopathic Arthritis; bDMARDs, biologic Disease Modifying Anti-Rheumatic Drugs; cDMARDs, conventional Disease Modifying Anti-Rheumatic Drugs; TST, Tuberculin skin test; IGRA, Interferon ɣ release assay; LTBI, latent tuberculosis infection; TB, tuberculosis
  3. *1Patients underwent the tuberculin skin test for different reasons (9), contact with sick relative (1) and suspected Tuberculosis case (1)
  4. *2Nonspecific pulmonary infiltrates and interstitial pulmonary infiltrates